Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire chooses Santaris as its partner for rare diseases; deal expanded

Executive Summary

RNA therapeutics developer Santaris Pharma AS will use its Locked Nucleic Acid (LNA) technology to identify and develop preclinical oligonucleotides against targets for rare genetic disorders selected by Shire Human Genetic Therapies, which receives worldwide development and commercialization rights to the compounds.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register